News | Wearables | February 20, 2024

X-trodes Receives FDA 510(k) Clearance for Wearable "Skin" Solution that Brings Medical-Grade Electrophysiological Monitoring to the Home

Next-generation skin patch-based monitoring platform enables complete freedom of movement for patients in both healthcare and home settings

Next-generation skin patch-based monitoring platform enables complete freedom of movement for patients in both healthcare and home settings

February 20, 2024 — X-trodes, a bio-convergence company bringing wireless monitoring solutions to the home environment, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for X-trodes' Smart Skin solution (marketed as X-trodes System M), a new wireless wearable technologyfor advanced electrophysiological monitoring. 

X-trodes’ Smart Skin is comprised of customizable dry-printed multi-modal electrode patches. It monitors a wide range of biopotential signals from anywhere on the body to acquire EEG (brain activity), EKG/ECG (cardiac monitoring), EOG (eye movement), and EMG (muscle activity) data. The discreet patches are easy to apply and comfortable to wear, conforming to the body without requiring gels, wires or uncomfortable solutions.

The FDA clearance follows successful completion of an extensive scientific assessment that evaluated the accuracy and consistency of X-trodes’ system. The study showed the performance of the X-trodes technology to be equivalent to that of FDA-cleared clinical electrophysiology devices in measuring EEG, EOG, EMG, and EKG/ECG signals.

“The X-trodes system is the next generation of wearable and fully wireless solutions, enabling clinicians and researchers to unleash the full potential of medical-grade electrophysiological monitoring,” said Ziv Peremen, PhD, CEO of X-trodes. “Gaining FDA clearance affirms the value of this technology and its potential to improve health and wellness through access to real-time electrophysiological data. It will further shorten the path to commercialization for a range of clinical use cases.”

Smart Skin is already available to researchers seeking unprecedented accuracy when measuring electrophysiological signals outside of laboratory settings. Having achieved FDA 510(k) clearance, X-trodes will pursue further validations for a wide range of clinical use cases, with an initial focus on the cardiovascular and sleep monitoring markets.

“Despite an abundance of legacy and new medical device companies entering the market, there is still no single configurable remote monitoring system capable of supporting neurology and cardiology departments in providing the best possible patient experience and outcomes," said Dr. Deganit Barak Shinar, VP of clinical affairs at X-trodes. “Our medical-grade multi-modal solution, which can be deployed across clinical departments and outpatient settings, including the home, has the potential to significantly improve the provision of care.”

Electrophysiological monitoring has traditionally been restricted to clinics, requiring cumbersome hardware and controlled environments to acquire highly sensitive physiological signals. X-trodes' Smart Skin encapsulates an entire monitoring lab into a discreet, flexible and completely wireless skin patch that provides continuous medical-grade monitoring in any environment that users may find themselves.

X-trodes' technology is backed by more than 15 years of research at Prof. Yael Hanein’s neuro engineering lab at Tel Aviv University and scientifically validated patents. Its efficacy has been supported by several peer-reviewed studies published in leading journals, including Nature Scientific Reports and the Journal of Neural Engineering.

For more information: htpps://xtrodes.com/


Related Content

News | FDA

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | FDA

July 29, 2024 — CorVascular, a leading producer of peripheral arterial disease (PAD) / peripheral vascular disease (PVD) ...

Home July 29, 2024
Home
News | FDA

July 2, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott has issued a correction for its ...

Home July 02, 2024
Home
News | FDA

June 18, 2024 — Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary ...

Home June 18, 2024
Home
News | FDA

June 17, 2024 — Elutia Inc., a pioneer in drug-eluting biomatrix products, today announced that its Antibiotic-Eluting ...

Home June 17, 2024
Home
News | FDA

June 13, 2024 — Xeltis, a leading developer of transformative implants that enable the natural creation of living and ...

Home June 13, 2024
Home
News | FDA

June 3, 2024 — Heuron, a specialized medical AI startup focused on brain and neurological disorders based in South Korea ...

Home June 03, 2024
Home
News | FDA

May 17, 2024 — Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has ...

Home May 17, 2024
Home
News | FDA

May 15, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling the HeartMate 3 LVAS by ...

Home May 15, 2024
Home
News | FDA

May 8, 2024 — The US Food and Drug Administration (FDA) is alerting health care providers and facilities about our ...

Home May 08, 2024
Home
Subscribe Now